<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290302</url>
  </required_header>
  <id_info>
    <org_study_id>1AZA10001</org_study_id>
    <nct_id>NCT01290302</nct_id>
  </id_info>
  <brief_title>Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Blinded Cross-over Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luitpold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luitpold Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the bioequivalence of subcutaneous Vidaza® and
      subcutaneous Luitpold Azacitidine pharmacokinetics and to assess the comparative safety of
      subcutaneous Vidaza® versus subcutaneous Luitpold Azacitidine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the bioequivalence of Vidaza® and Luitpold Azacitidine pharmacokinetics, in terms
      of Cmax, AUC0-t and AUC0-∞, following SC administration.

      To assess the comparative safety of Vidaza® versus Luitpold Azacitidine during the 2 day
      study period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the Concentration Time Curve (AUC0-t)</measure>
    <time_frame>Blood will be drawn pre-dose, and 0.125, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 10 hours after dosing on days 1 and 2</time_frame>
    <description>Pharmacokinetic Analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Concentration Time Curve Extrapolated to Infinity (AUC0-∞)</measure>
    <time_frame>Blood will be drawn pre-dose, and 0.125, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 10 hours after dosing on days 1 and 2</time_frame>
    <description>Pharmacokinetic Analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed maximal concentration (Cmax)</measure>
    <time_frame>Blood will be drawn pre-dose, and 0.125, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 10 hours after dosing on days 1 and 2</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myelofibrosis</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Luitpold Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vidaza®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luitpold Azacitidine</intervention_name>
    <description>Subcutaneous (SC) at a dose of 75 mg/m2 per day on days 1 and 2 of a treatment cycle</description>
    <arm_group_label>Luitpold Azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vidaza®</intervention_name>
    <description>Subcutaneous (SC) at a dose of 75 mg/m2 per day on days 1 and 2 of a treatment cycle</description>
    <arm_group_label>Vidaza®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent obtained prior to initiation of any study-specific procedures.

          -  Patients with one of the following - myelodysplastic syndrome of the following
             French-American- British (FAB) subtypes: refractory anemia (RA), RA with ringed
             sideroblasts (if accompanied by neutropenia, or thrombocytopenia, or requiring
             transfusion), RA with excess of blasts (RAEB), RAEB in transformation (RAEB-T), or
             chronic myelomonocytic leukemia (CMMoL); myelofibrosis; chronic myeloid leukemia; or
             chronic lymphocytic leukemia who's physician feels should receive azacitidine.

          -  Male or female patients aged at least 18 years.

          -  ECOG Performance Status 0-2.

          -  Life expectancy &gt; or = to 3 months.

          -  Adequate organ function, including the following: Hepatic - Total bilirubin &lt; or = to
             1.5 x the upper limit of normal (ULN), aspartate transaminases (AST) and alanine
             transaminases (ALT) &lt; or = to 2 x ULN and Renal - Serum creatinine &lt; or = to 1.5 x
             ULN.

          -  Female patients of child-bearing potential must have a negative pregnancy test and
             must be using at least one form of contraception as approved by the Investigator for 4
             weeks prior to the study and 4 months after the last dose of azacitidine.

          -  Male patients must use a form of barrier contraception approved by the investigator
             during the study and for 4 months after the last dose of azacitidine.

        Exclusion Criteria:

          -  Hypersensitivity to azacitidine or mannitol.

          -  Anticipated need for RBC or platelet transfusion 2 days prior to or up to 2 days after
             treatment initiation.

          -  Chemotherapy (excluding previous azacitidine treatment) or radiotherapy within 4 weeks
             of randomization (6 weeks for nitrosoureas or mitomycin C).

          -  Significant electrophysical abnormalities in pre-trial EKG.

          -  Present history of locally advanced or metastatic malignant disease or leukemia.

          -  Use of recreational drugs or history of drug addiction, within the prior 6 months.

          -  Known history of a positive hepatitis screen, including hepatitis B surface antigens
             or HCV antibodies.

          -  Known history of HIV or syphilis.

          -  History of clinically significant adverse events due to chemotherapy, radiotherapy or
             investigational agents.

          -  Presence of an advanced malignant hepatic tumor.

          -  Presence of an ongoing or active infection, symptomatic congestive heart failure,
             unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia,
             uncontrolled thrombotic or hemorrhagic disorder, or any other serious uncontrolled
             medical disorders.

          -  Presence of any significant central nervous system or psychiatric disorder(s) that
             would hamper the patients compliance.

          -  Treatment with any other investigational agent, or participation in another clinical
             trial within 28 days prior to study entry.

          -  Pregnant or breast-feeding patients or any patient with childbearing potential not
             using adequate contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Luitpold Pharmaceuticals, Inc.</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2011</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

